SPOTLIGHT -
Slideshow
Author(s):
Up to 50% of cases of cannabis-induced psychosis covert to schizophrenia. A new study provides striking evidence for abuse of other substances and schizophrenia onset.
FDA Committees Vote to Dismiss Clozapine REMS
Treating ‘Morally Objectionable’ Patients
Long-Acting Injectables and a Team-Driven Approach for Schizophrenia Treatment
More Than Postpartum Depression: Addressing Maternal Mental Health Through the Life Cycle
Emraclidine for Schizophrenia Fails to Meet Primary Endpoints in Phase 2 EMPOWER Trials
Schizophrenia Pharmacology: Version 2.0